Clinical Trials for Small Cell Lung Cancer

A Phase II Trial of GT103 in Combination With Pembrolizumab in STK11 Mutant Non-Small Cell Lung Cancer (NSCLC)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: For adults with advanced or metastatic STK11-mutant NSCLC who have progressed on a pembrolizumab-containing regimen and are eligible to continue pembrolizumab, this study adds intravenous GT103 to pembrolizumab. GT103 is an investigational antibody targeting tumor-associated complement factor H.

ClinicalTrials.gov ID: NCT07017829

A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with measurable relapsed extensive-stage SCLC after one platinum-based regimen and ECOG performance status 0–1 are randomized to ifinatamab deruxtecan or physician’s choice of topotecan, lurbinectedin, or amrubicin. Ifinatamab deruxtecan is an investigational B7-H3–targeted antibody–drug conjugate that delivers a topoisomerase I inhibitor.

ClinicalTrials.gov ID: NCT06203210

A Phase 2 Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with extensive-stage SCLC that progressed during or after platinum-based chemotherapy and anti-PD-L1 therapy, with no more than two prior systemic treatment lines, receive oral alisertib monotherapy. Alisertib inhibits Aurora A kinase, disrupting cell division; the study evaluates outcomes in biomarker-defined subgroups.

ClinicalTrials.gov ID: NCT06095505

A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: For patients with previously untreated extensive-stage small cell lung cancer, preserved functional status, and measurable disease outside the CNS, this trial compares carboplatin/etoposide plus BMS-986489 with carboplatin/etoposide plus atezolizumab. BMS-986489 combines BMS-986012, an antibody targeting fucosyl-GM1 on SCLC cells to promote immune-mediated killing, with the PD-1 inhibitor nivolumab.

ClinicalTrials.gov ID: NCT06646276

A Ph2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab Versus Placebo, in Combination With Pembrolizumab, Pemetrexed, and Carboplatin, in 1L Treatment of Participants With Metastatic NSCLC (GDFATHER-NSCLC-01)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with untreated stage IV nonsquamous NSCLC, ECOG 0–1, and no actionable alteration warranting targeted therapy receive first-line pembrolizumab, pemetrexed, and carboplatin plus visugromab or placebo. Visugromab is an investigational antibody that neutralizes GDF-15 to potentially enhance antitumor T-cell activity.

ClinicalTrials.gov ID: NCT07098988

A Phase II, Open Label, Multicenter, Single Arm Study of WSD0922-FU for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With First-Line Osimertinib Treatment and Harbor a C797S Mutation

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with locally advanced or metastatic EGFR C797S-mutated NSCLC that progressed on first-line osimertinib receive oral WSD0922-FU twice daily at one of two dose levels. WSD0922-FU is an investigational reversible EGFR inhibitor designed to target sensitizing EGFR mutations and C797S-mediated resistance.

ClinicalTrials.gov ID: NCT06868485

A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with previously untreated, unresectable stage IIIB/IIIC or metastatic KRAS G12C-mutant nonsquamous NSCLC receive either oral calderasib (MK-1084), an investigational KRAS G12C inhibitor, plus subcutaneous pembrolizumab–berahyaluronidase alfa, or pembrolizumab–berahyaluronidase alfa plus pemetrexed and carboplatin or cisplatin. The primary analysis assesses progression-free survival in patients with PD-L1 TPS ≥1%.

ClinicalTrials.gov ID: NCT07190248

A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with previously untreated, advanced or metastatic KRAS G12C-mutated nonsquamous NSCLC who are eligible for platinum chemotherapy are randomized to divarasib, an investigational KRAS G12C inhibitor, plus pembrolizumab or to pembrolizumab, pemetrexed, and carboplatin or cisplatin.

ClinicalTrials.gov ID: NCT06793215

A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY TO EVALUATE PF-08046054/SGN-PDLlV VERSUS DOCETAXEL IN ADULT PARTICIPANTS WITH PREVIOUSLY-TREATED PROGRAMMED CELL DEATH LIGAND 1 (PD-Ll) POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable stage IIIB/IIIC or metastatic PD-L1-positive NSCLC (≥1%) who have progressed after platinum-based therapy and applicable immunotherapy or targeted therapy are randomized to PF-08046054 (fetrastobart vedotin) or docetaxel. PF-08046054 is a PD-L1-targeting antibody–drug conjugate that delivers the microtubule-disrupting payload monomethyl auristatin E.

ClinicalTrials.gov ID: NCT07144280

A Study of Open-label Orally Administered JBI-802 Alone or in Combination With Pembrolizumab in Patients With Advanced NSCLC Tumors Harboring an STK11 Mutation

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with locally advanced or metastatic STK11-mutated NSCLC receive oral JBI-802, an investigational dual LSD1/KDM1A and HDAC6 inhibitor, either alone or with the PD-1 inhibitor pembrolizumab. Eligible patients have measurable disease and ECOG performance status 0–2.

ClinicalTrials.gov ID: NCT07207395